Loading...
XNAS:REPL
Replimune shares are trading lower after facing multiple class action lawsuits alleging securities fraud due to misleading statements about their IGNYTE trial, which the FDA deemed inadequate.
Replimune Group shares are trading higher despite recent announcements of multiple class action lawsuits related to alleged securities fraud, possibly driven by investor confidence in the company's long-term potential or other positive market factors.
Replimune Group shares are trading lower after The Rosen Law Firm filed a class action lawsuit alleging the company made materially false statements regarding the IGNYTE trial's prospects.
Replimune Group shares are trading higher as investors find relief amid multiple securities class action filings, focusing on potential legal resolutions and company transparency improvements.